Interstitial lung disease: retrospective study of the prognostic impact of acute exacerbations.

Joana Pacheco, Ana Isabel Santos, Maria Joana Catarata, Sara Freitas
{"title":"Interstitial lung disease: retrospective study of the prognostic impact of acute exacerbations.","authors":"Joana Pacheco, Ana Isabel Santos, Maria Joana Catarata, Sara Freitas","doi":"10.36141/svdld.v41i4.15198","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Interstitial lung diseases have high mortality associated with hospitalization for decompensation. There are doubts about the factors involved in the progression of fibrosis, for example the role played by acute exacerbations.  With this work, the authors intend to analyze whether there are predictive parameters of mortality related to exacerbations.</p><p><strong>Methods: </strong>A retrospective study was carried out of patients admitted to the Pulmonology department of Coimbra University Hospital Center for exacerbation of fibrosing lung disease between January 2019 and December 2020. These were classified as: idiopathic pulmonary fibrosis (IPF), fibrosing hypersensivity pneumonitis (FHP) and other fibrosing lung diseases. Statistical analysis was performed using SPSS 26.0 considering statistically significant p<0.05 values.</p><p><strong>Results: </strong>The results show that IPF is associated with longer hospital stay in relation to fibrosing HP and other fibrosing lung diseases mean of 20.93 days (95% CI: 14.69-27.18) vs 11.8 days (95% CI: 1.05-17.22, p=0.023) vs 12.23 days (95% CI 2.06-15.34, p=0.007), respectively. Regarding mortality, there was no difference between IPF, PH and other fibrosing diseases (p=0.631).</p><p><strong>Conclusion: </strong>This study demonstrated that IPF, compared to PH and other fibrosing diseases, is associated with longer hospital stays, probably due to its progressive course despite the institution of corticosteroid therapy. As shown in previous studies, it was concluded that there is no difference in terms of mortality between IPF exacerbations and other forms of fibrosing lung disease.</p>","PeriodicalId":502142,"journal":{"name":"Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG","volume":"41 4","pages":"e2024051"},"PeriodicalIF":0.0000,"publicationDate":"2024-12-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11708956/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.36141/svdld.v41i4.15198","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Interstitial lung diseases have high mortality associated with hospitalization for decompensation. There are doubts about the factors involved in the progression of fibrosis, for example the role played by acute exacerbations.  With this work, the authors intend to analyze whether there are predictive parameters of mortality related to exacerbations.

Methods: A retrospective study was carried out of patients admitted to the Pulmonology department of Coimbra University Hospital Center for exacerbation of fibrosing lung disease between January 2019 and December 2020. These were classified as: idiopathic pulmonary fibrosis (IPF), fibrosing hypersensivity pneumonitis (FHP) and other fibrosing lung diseases. Statistical analysis was performed using SPSS 26.0 considering statistically significant p<0.05 values.

Results: The results show that IPF is associated with longer hospital stay in relation to fibrosing HP and other fibrosing lung diseases mean of 20.93 days (95% CI: 14.69-27.18) vs 11.8 days (95% CI: 1.05-17.22, p=0.023) vs 12.23 days (95% CI 2.06-15.34, p=0.007), respectively. Regarding mortality, there was no difference between IPF, PH and other fibrosing diseases (p=0.631).

Conclusion: This study demonstrated that IPF, compared to PH and other fibrosing diseases, is associated with longer hospital stays, probably due to its progressive course despite the institution of corticosteroid therapy. As shown in previous studies, it was concluded that there is no difference in terms of mortality between IPF exacerbations and other forms of fibrosing lung disease.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
间质性肺疾病:急性加重对预后影响的回顾性研究。
背景:间质性肺疾病与住院治疗代偿失代偿相关的死亡率很高。对于参与纤维化进展的因素存在疑问,例如急性加重所起的作用。通过这项工作,作者打算分析是否存在与恶化相关的死亡率的预测参数。方法:对2019年1月至2020年12月在科英布拉大学医院中心肺病科因纤维化性肺病加重入院的患者进行回顾性研究。这些疾病被分类为:特发性肺纤维化(IPF)、纤维化超敏性肺炎(FHP)和其他纤维化肺部疾病。结果显示,IPF与纤维化性HP和其他纤维化性肺部疾病的住院时间相关,平均为20.93天(95% CI: 14.69 ~ 27.18) vs 11.8天(95% CI: 1.05 ~ 17.22, p=0.023) vs 12.23天(95% CI: 2.06 ~ 15.34, p=0.007)。在死亡率方面,IPF、PH与其他纤维化疾病无差异(p=0.631)。结论:本研究表明,与PH和其他纤维化疾病相比,IPF与更长的住院时间有关,这可能是由于尽管采用了皮质类固醇治疗,但IPF的病程仍在进展。先前的研究表明,IPF加重与其他形式的纤维化肺疾病在死亡率方面没有差异。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Sarcoidosis after Alemtuzumab therapy: Is Alemtuzumab posing a threat to its patients? Sarcoidosis in north African people: about 35 cases. Online survey on existing sarcoidosis registries and biobanks: an ERN lung initiative. Prevalence of SARS-COV-2 infection and outcomes in Greek sarcoidosis patients. Prolonged corticosteroid therapy and lung abnormalities in patients after severe COVID-19 pneumonia.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1